CEPHA center

To strengthen its antibiotic business, Daewoong Bio has built a KRW 55 billion Cephalosporin plant in Hwaseong, Gyeonggi. Scheduled for completion in May 2025, the plant aims for GMP certification and full-scale production by December. With doubled production capacity (300 million tablets, 20 million vials), dedicated CMO lines, and optimized quality systems, it will ensure stable medicine supply and long-term business competitiveness.
